Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MLYCD | O95822 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14518464 | 0.85 | HDAC4 (0.51) | NAMPTKMT2AMLYCDLMNAHDAC4 | |
| SCHEMBL5710878 | 0.82 | HPGD (0.56) | KDM4EKMT2AMLYCDLMNANAPRT | |
| SCHEMBL23304109 | 0.81 | KDM4E (0.54) | NAMPTKDM4EKMT2APOLBMMP13 | |
| SCHEMBL7606752 | 0.80 | KDM4E (0.49) | NAMPTKDM4EKMT2AMLYCDLMNA | |
| SCHEMBL10128312 | 0.79 | KDM4E (0.49) | NAMPTKDM4EKMT2APOLBMMP13 | |
| SCHEMBL18735505 | 0.79 | KDM4E (0.49) | NAMPTKDM4EKMT2APOLBMMP13 | |
| SCHEMBL1003249 | 0.79 | ALDH1A1 (0.58) | KMT2AALDH1A1 | |
| SCHEMBL353139 | 0.79 | KDM4E (0.60) | KDM4EKMT2AMLYCDLMNAHTT | |
| Water SCHEMBL27826394 | 0.78 | NAMPT (0.47) | NAMPTKMT2AMMP13MLYCDLMNA | |
| SCHEMBL27854800 | 0.78 | KDM4E (0.47) | NAMPTKDM4EKMT2AMLYCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678466-B | Diazanaphthalenes as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-9849107-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | SEQUOIA PHARMACEUTICALS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170101429-A1 | METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| US-20170081346-A1 | MESOSCOPIC MATERIALS COMPRISED OF ORDERED SUPERLATTICES OF MICROPOROUS METAL-ORGANIC FRAMEWORKS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-03-23 | — | — | US | disclosed |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9233952-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| WO-2015195179-A2 | METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015161037-A1 | VERY LOW DENSITY METAL ORGANIC FRAMEWORKS WITH LARGE PORE VOLUMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015157239-A1 | FUNCTIONALIZED AND MULTIVARIATE BTB-BASED METAL ORGANIC FRAMEWORKS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-15 | — | — | WO | disclosed |
| US-8673970-B2 | HIV protease inhibitor and cytochrome p450 inhibitor combinations | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS INC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8481520-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8048871-B2 | Inhibitors that when coadministered with a drug that undergoes in vivo degradation by cytochrome P450 enzyme, improves the pharmacokinetics, bioavailability and disease treatment such as of HIV, Hepatitis C virus, diabetes, epilepsy, cancer, depression; amide or sulfonamide-functional benzofurans | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-7772239-B2 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080070923-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-20 | — | — | US | disclosed |
| US-7317022-B2 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| WO-2007039218-A1 | HIV INTEGRASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2007-04-12 | — | — | WO | disclosed |
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | NAMPT 1259/4885KDM4E 2502/4885KMT2A 3386/4885 |
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | HTR4, HTR5A, HTR1A | NAMPT 1641/4885KDM4E 1082/4885KMT2A 2365/4885 |
| US-20170081346-A1 | MESOSCOPIC MATERIALS COMPRISED OF ORDERED SUPERLATTICES OF MICROPOROUS METAL-ORGANIC FRAMEWORKS | MCM2, YTHDF2, MCM6 | NAMPT 977/4885KDM4E 1665/4885KMT2A 551/4885 |
| US-20170101429-A1 | METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS | EPCAM, SOD1, SBDS | NAMPT 2946/4885KDM4E 3868/4885KMT2A 2617/4885 |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | NAMPT 1259/4885KDM4E 2502/4885KMT2A 3386/4885 |
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | HCCS, CYP2E1, CYP7A1 | NAMPT 985/4885KDM4E 1695/4885KMT2A 2347/4885 |
| US-20080070923-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | NAMPT 1685/4885KDM4E 1073/4885KMT2A 2371/4885 |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | NAMPT 1259/4885KDM4E 2502/4885KMT2A 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.